SCHEMBL12377075

SCHEMBL12377075

CCCOc1ccccc1CCCNC

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 3/20 0.60
L3MBTL1 Q9Y468 2/20 0.59
TP53 P04637 1/20 0.59
CYP1A2 P05177 1/20 0.59
CYP3A4 P08684 1/20 0.59
CYP2C9 P11712 1/20 0.59
TSHR P16473 1/20 0.59
LMNA P02545 1/20 0.57
SLC6A4 P31645 2/20 0.50
HTR1B P28222 2/20 0.46
PPARD Q03181 1/20 0.46
MTNR1A P48039 1/20 0.44
MTNR1B P49286 1/20 0.44
HTR1D P28221 1/20 0.44
MAPT P10636 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2909676 0.90 HRH1 (0.55) HRH1L3MBTL1TP53CYP1A2CYP3A4
SCHEMBL24712708 0.87 HRH1 (0.55) HRH1L3MBTL1TP53CYP1A2CYP3A4
SCHEMBL8986167 0.86 HRH1 (0.59) HRH1L3MBTL1TP53CYP1A2CYP3A4
SCHEMBL2910225 0.85 HRH1 (0.58) HRH1L3MBTL1TP53CYP1A2CYP3A4
SCHEMBL73826 0.84 CYP1A2 (0.52) L3MBTL1CYP1A2CYP2C9PPARDMAPT
SCHEMBL10150312 0.83 ALOX5 (0.51) L3MBTL1CYP1A2CYP2C9PPARDMAPT
SCHEMBL11717347 0.81 THRA (0.54) L3MBTL1CYP1A2CYP3A4CYP2C9LMNA
SCHEMBL19289404 0.81 THRA (0.54) L3MBTL1CYP1A2CYP3A4CYP2C9LMNA
SCHEMBL74512 0.81 PPARD (0.54) L3MBTL1CYP1A2CYP2C9SLC6A4PPARD
SCHEMBL9241990 0.80 HRH1 (0.60) HRH1L3MBTL1TP53CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409945-B2 Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery OCERA THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150315235-A1 Combinatorial Synthesis of Libraries of Macrocyclic Compounds Useful in Drug Discovery MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.) 2015-11-05 US disclosed
US-8008440-B2 Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery TRANZYME PHARMA INC. (CA) 2011-08-30 US disclosed
US-20070117154-A1 Cyclic lactams comprising three amino acids and a tether chain to control the overall shape of the macromolecule; beta-turn mimetics to explore conformationally restricted structures; proteolytic enzyme resistance (nonhydrolyzing); cell penetration; anticoagulants; anticarcinogenic agents MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED (IE) 2007-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117154-A1 Cyclic lactams comprising three amino acids and a tether chain to control the overall shape of the macromolecule; beta-turn mimetics to explore conformationally restricted structures; proteolytic enzyme resistance (nonhydrolyzing); cell penetration; anticoagulants; anticarcinogenic agents F2, BCAT1, DAO HRH1 3782/4885L3MBTL1 1819/4885TP53 3173/4885
US-20150315235-A1 Combinatorial Synthesis of Libraries of Macrocyclic Compounds Useful in Drug Discovery COASY, SCO2, CCNO HRH1 3384/4885L3MBTL1 2306/4885TP53 2476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.